Volume 14, Number 2—February 2008
Research
Cost-effectiveness of Human Papillomavirus Vaccination in the United States
Harrell W. Chesson*
, Donatus U. Ekwueme*, Mona Saraiya*, and Lauri E. Markowitz*
, Donatus U. Ekwueme*, Mona Saraiya*, and Lauri E. Markowitz*
Table 1
Estimated cost per QALY gained by adding routine HPV vaccination of 12-y-old girls to existing cervical cancer screening in the United States*
| Parameter | Population model |
Cohort model; no herd immunity, $US | |
|---|---|---|---|
| No herd immunity, $US | Herd immunity, $US | ||
| Excluding anal, vaginal, vulvar, and oropharyngeal cancers | |||
| Vaccine targets HPV types 6,11,16,18 | 10,294 | 5,336 | 8,593 |
| Vaccine targets HPV types 16,18 |
14,723 |
10,318 |
12,562 |
| Including anal, vaginal, vulvar, and orophayngeal cancers† | |||
| Vaccine targets HPV types 6,11,16,18 | 8,137 | 3,906 | 6,430 |
| Vaccine targets HPV types 16,18 | 11,602 | 7,848 | 9,471 |
*When applying base-case parameter values to 12 model variations. QALY, quality-adjusted life year; HPV, human papillomavirus.
†The oropharyngeal cancer sites we included were base of tongue, tonsillar, and other sites as described in the Technical Appendix.
Page created: July 21, 2010
Page updated: July 21, 2010
Page reviewed: July 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.